CD274 and non-small cell lung carcinoma: This study contributes to the growing literature describing the poor clinical outcomes among patients with NSCLC who experience progression on anti–PD-(L)1 and platinum-doublet chemotherapy, highlighting the large unmet need for additional treatment options that may improve survival in later lines of therapy.